Thierry Poynard

USPTO Granted Patents = 8 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 1.1

ph-index = 3

Forward Citations = 54(Granted Patents)

Company Filing History:

4 out of 61

Assistance Publique - Hopitaux De Paris (aphp)

Assistance Publique-hopitaux De Paris

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12487243 - Method of diagnosis of infection by the SARS-CoV-2 virus (2025-12-02),

2. 12360113 - Method of prognosis and follow up of primary liver cancer (2025-07-15),

3. 11965894 - Method of diagnosis of drug induced liver injury (2024-04-23),

4. 10198552 - Method of diagnosis of fibrotic diseases (2019-02-05),

5. 7860656 - Diagnosis method of hepatic steatosis using biochemical markers (2010-12-28),

6. 7856319 - Diagnosis method of alcoholic steato-hepatitis using biochemical markers (2010-12-21),

7. 7225080 - Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers (2007-05-29),

8. 6631330 - Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers (2003-10-07),

Title: Innovations by Thierry Poynard

Introduction

Thierry Poynard is a notable inventor based in Paris, France. He has made significant contributions to the field of medical diagnostics, particularly concerning liver diseases. With a total of seven patents to his name, Poynard's work focuses on improving the prognosis and diagnosis of liver-related conditions.

Latest Patents

Among his latest patents is a method for prognosis and follow-up of primary liver cancer. This invention relates to new methods for assessing the risk of a patient, especially those with chronic liver disease, to develop primary liver cancer over time. It utilizes functions that combine blood biochemical markers for more accurate assessments. Another significant patent is a method for diagnosing drug-induced liver injury (DILI). This invention introduces new methods for assessing the prognosis of recovery from DILI in a patient, combining the measurement of serum markers through a logistic function that excludes bilirubin and transaminases (AST and ALT) markers.

Career Highlights

Throughout his career, Thierry Poynard has worked with prominent institutions, including Assistance Publique - Hôpitaux de Paris and Biopredictive. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Thierry Poynard's contributions to medical diagnostics, particularly in liver disease, highlight his innovative spirit and dedication to improving patient care. His patents reflect a commitment to advancing medical technology and enhancing the accuracy of diagnoses.

This text is generated by artificial intelligence and may not be accurate.